Search results for "nephropathy"

showing 10 items of 85 documents

Microalbuminuria fractional clearance and early renal permselectivity changes in essential hypertension.

1992

In order to verify if, in essential hypertension (EH), the microalbuminuria (AER) increase could be due to hemodynamic modifications or to glomerular structural changes, in 15 essential hypertensives (EHs) with 24-hour AER16 micrograms/min and in 15 EHs with 24-hour AERor = 16 micrograms/min, the day- and nighttime behavior of creatinine clearance (Ccr), as well as AER clearance (AER-C) and fractional clearance (AER-FC), and behavior of blood pressure (BP) was evaluated. Patients with 24-hour AER16 micrograms/min showed significantly higher values of 24-hour and daytime Ccr than the other group of EHs, while during the night period, there were no significant differences between the two grou…

Adultmedicine.medical_specialtyanimal structuresCell Membrane Permeabilityendocrine system diseasesRenal functionHemodynamicsurologic and male genital diseasesEssential hypertensionKidneyNephropathyInternal medicinemedicineAlbuminuriaHumansLeast-Squares AnalysisProteinuriabusiness.industryAlbuminmedicine.diseasefemale genital diseases and pregnancy complicationsBlood Pressure MonitorsCircadian RhythmBlood pressureEndocrinologyNephrologyHypertensionMicroalbuminuriamedicine.symptombusinesshuman activitiesGlomerular Filtration RateAmerican journal of nephrology
researchProduct

Anti-C1q Autoantibodies in Lupus Nephritis: Prevalence and Clinical Significance

2005

Recently, anti-C1q autoantibodies have been proposed as a useful marker in systemic lupus erythematosus (SLE) since their occurrence correlates with renal involvement and, possibly, with nephritic activity. We aimed to evaluate the prevalence of anti-C1q antibodies in patients with SLE, with and without renal involvement, and to correlate these markers' presence and levels with the activity of the disease and nephropathy. We studied 61 patients with SLE, 40 of whom had biopsy-proven lupus nephritis; 35 patients with other connective tissue diseases; and 54 healthy controls. In addition, 18 lupus nephritis patients were followed up during the disease time course. Anti-C1q antibodies were mea…

BiopsySLELupus nephritisEnzyme-Linked Immunosorbent AssaySystemic lupus erythematosuAnti-DNA antibodieSeverity of Illness IndexGeneral Biochemistry Genetics and Molecular BiologyFollow-Up StudieNephropathyCohort StudiesHistory and Philosophy of Scienceimmune system diseasesAutoimmune diseasePrevalencemedicineHumansLupus Erythematosus SystemicConnective Tissue DiseasesGlomerulonephritiskin and connective tissue diseasesRenal flareConnective Tissue DiseaseAutoantibodiesAutoimmune diseaseBiochemistry Genetics and Molecular Biology (all)Systemic lupus erythematosusbusiness.industryLupus nephritiComplement C1qGeneral NeuroscienceAutoantibodyGlomerulonephritisBiomarkermedicine.diseaseLupus NephritisAutoantibodieAntibodies Anti-IdiotypicItalyAntibodies AntinuclearImmunologyAnti-C1q antibodieCohort StudiebusinessNephritisBiomarkersFollow-Up StudiesHumanAnti-SSA/Ro autoantibodiesAnnals of the New York Academy of Sciences
researchProduct

Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients.

2011

Our aim was to investigate u-NGAL, u-KIM1 and p-FGF23 and prediction of decline in kidney function in type 2 diabetic patients with proteinuria.We performed a follow-up study, follow-up median (range) 3.5 (1-5) years. At baseline u-NGAL, u-KIM1 and p-FGF23 (ELISA) was measured and patients were followed yearly with estimated(e)-GFR (MDRD) and u-albumin.We included 177 patients (44 women), mean age (SD) 59 (9) years. eGFR 90 (24) ml/min/1.73 m(2) at baseline, u-albumin: median (interquartile range) 104 (39-238) mg/24 h. Patients with levels of u-KIM1 in the highest quartile had a greater decline in eGFR than patients with the lowest quartile 6.0 (5.4) versus 3.2 (5.5) ml/min/1.73 m(2) per ye…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismUrologyRenal functionEnzyme-Linked Immunosorbent AssayType 2 diabetesKidneyEnd stage renal diseaseDiabetic nephropathyEndocrinologyInterquartile rangeDiabetes mellitusInternal medicineInternal MedicinemedicineHumansDiabetic NephropathiesProteinuriabusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseFibroblast Growth Factor-23ProteinuriaEndocrinologyKidney TubulesQuartileDiabetes Mellitus Type 2Disease ProgressionFemalemedicine.symptombusinessBiomarkersAcute-Phase ProteinsFollow-Up StudiesGlomerular Filtration RateDiabetes research and clinical practice
researchProduct

Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics.

2001

Background. The aim of the present study was to assess the antialbuminuric effect of losartan in a large number of hypertensive type 2 diabetics. Methods. This was a 6-month, open-label, prospective and multicentre study. A total of 422 patients with type 2 diabetes who were hypertensive [sitting systolic blood pressure (SBP) > 140 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg] and microalbuminuric [urinary albumin excretion (UAE) 30-300 mg/day] were eligible for the study. After a 2-week run-in period, patients were placed on losartan 50 mg once a day. If the BP did not reach the desired goal (<140/90 mmHg) after a 4-week period, the losartan dose was doubled. In the absence of contr…

Blood Glucosemedicine.medical_specialtySystoleUrologyRenal functionBlood PressureType 2 diabetesLosartanDiabetic nephropathyDiastoleDiabetes mellitusInternal medicinemedicineAlbuminuriaHumansAntihypertensive AgentsGlycated HemoglobinTransplantationbusiness.industryBody Weightmedicine.diseaseAngiotensin IIUric AcidLosartanEndocrinologyBlood pressureHydrochlorothiazideDiabetes Mellitus Type 2NephrologyHypertensionRegression AnalysisMicroalbuminuriaDrug Therapy CombinationbusinessDiabetic Angiopathiesmedicine.drugNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
researchProduct

Early deaths in acute lymphoblastic leukemia (ALL): results of the Italian Pediatric Cooperative Group for Therapy of Acute Leukemia (AIL-AIEOP).

1984

In this retrospective multicentric study, we report on early deaths (ie, those that occurred during the first month of treatment) in a total of 943 newly diagnosed ALL pediatric patients registered from 1976 to 1981 at 21 centers of the AIL-AIEOP. Objectives of this study were as follows: (1) to verify the incidence and the cause of early death in a wide population of children with ALL and (2) to elucidate factors associated with early death and therefore to identify “high-risk” groups of patients. Out of the 943 ALL patients, 39 (4.1%) early deaths were registered. Main causes were infection, 20 patients (51.3%); hemorrhage, 11 patients (28.3%); uric acid nephropathy, 2 patients (5.1%); ca…

Cancer ResearchPediatricsmedicine.medical_specialtyAdolescentHeart DiseasesLymphoblastic LeukemiaPopulationEarly deathHemorrhageInfectionsMediastinal NeoplasmsNephropathyAntineoplastic Combined Chemotherapy ProtocolsmedicineHumanseducationChildRetrospective Studieseducation.field_of_studyAcute leukemiabusiness.industryIncidence (epidemiology)Age FactorsMediastinumInfantmedicine.diseasePrognosisLeukemia Lymphoidmedicine.anatomical_structureOncologyChild PreschoolPediatrics Perinatology and Child HealthSyndrome of inappropriate antidiuretic hormone secretionKidney DiseasesbusinessMedical and pediatric oncology
researchProduct

P5

2013

Background Pathogenic action of nitric oxide (NO) is responsible to a large extent for development of complications of the diabetes mellitus (DM). NO overproduction is largerly responsible for development of diabetic nephropathy. Thus search for compounds modifying NO production appears to be important for development of pharmacological remedies for treatment of DM complications. Dihydropiridines (DHP) appear to be prospective compounds from this point of view. The goal of the present work was to study alterations of NO production in streptozotocin model of DM in rats and ability of several DHPs and to normalize NO synthesis in kidneys of these animals. Methods Diabetes mellitus was induced…

Cancer Researchmedicine.medical_specialtyOxidase testbiologyPhysiologyClinical BiochemistryAllopurinolmedicine.diseaseStreptozotocinbiology.organism_classificationBiochemistryNitric oxideDiabetic nephropathychemistry.chemical_compoundEndocrinologychemistryEnosInternal medicineDiabetes mellitusmedicineXanthine oxidasemedicine.drugNitric Oxide
researchProduct

Anderson-Fabry Disease: A Multiorgan Disease

2013

Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by a deficiency of the enzyme α-galactosidase A . FD causes glycolipids, such as globotriaosylceramide (Gb3), to accumulate in the vascular endothelium of several organs (fig.2), including the skin, kidneys, nervous system, and heart, thereby triggering inflammation and fibrosis . These processes generally result in organ dysfunction, which is usually the first clinical evidence of FD. Patients with classic FD have various symptoms, eg, acroparesthesias, hypohidrosis, angiokeratomas, corneal opacities, cerebrovascular lesions, cardiac disorders, andrenal dysfunction.However, evolving knowledge about the natural course o…

Central Nervous SystemMalePathologymedicine.medical_specialtySettore MED/09 - Medicina InternaGlobotriaosylceramideDiseaseKidneySeverity of Illness IndexAnderson-Fabry disease multiorgan lysosomialNephropathychemistry.chemical_compoundDrug DiscoverymedicineHumansEnzyme Replacement TherapyEndothelial dysfunctionSkinPharmacologySex Characteristicsbusiness.industryOrgan dysfunctionAge FactorsKidney metabolismEnzyme replacement therapymedicine.diseaseFabry diseasechemistryQuality of LifeFabry DiseaseFemalemedicine.symptombusinessCurrent Pharmaceutical Design
researchProduct

Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen

2019

BACKGROUND: Although diabetic kidney disease demonstrates both familial clustering and single nucleotide polymorphism heritability, the specific genetic factors influencing risk remain largely unknown.METHODS: To identify genetic variants predisposing to diabetic kidney disease, we performed genome-wide association study (GWAS) analyses. Through collaboration with the Diabetes Nephropathy Collaborative Research Initiative, we assembled a large collection of type 1 diabetes cohorts with harmonized diabetic kidney disease phenotypes. We used a spectrum of ten diabetic kidney disease definitions based on albuminuria and renal function.RESULTS: Our GWAS meta-analysis included association result…

Collagen Type IVMale0301 basic medicineEXPRESSIONNEPHROPATHY030232 urology & nephrologyPROTEINGenome-wide association studyRECEPTOR TYROSINE KINASESBiologySUSCEPTIBILITYBioinformaticsurologic and male genital diseasesAutoantigensNephropathyEnd stage renal diseaseCohort StudiesDiabetic nephropathy03 medical and health sciences0302 clinical medicineSDG 3 - Good Health and Well-beingDiabetes mellitusGlomerular Basement MembranemedicineHumansDiabetic NephropathiesAlport syndromeLetter to the EditorCOMPLICATIONSNITRIC-OXIDEMUTATIONS1184 Genetics developmental biology physiologyGeneral Medicinemedicine.diseaseGENE3. Good healthDiabetes Mellitus Type 1030104 developmental biologyNephrology3121 General medicine internal medicine and other clinical medicineMutationAlbuminuria/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemale3111 Biomedicinemedicine.symptomCOLLECTIN 11 CL-11Genome-Wide Association StudyKidney disease
researchProduct

Behavior of patients at high risk of developing contrast induced nephropathy after coronary procedures

2012

Contrast induced nephropathy atherosclerosis percutaneous coronary intervention coronary angiography
researchProduct

MECHANISM OF DIABETIC NEPHROPATHY: ROLE OF VEGF-A

Diabetes; DIABETIC NEPHROPATHY; VEGFDIABETIC NEPHROPATHYDiabeteVEGF
researchProduct